[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100528680":3},{"organization":4,"outcomesModule":7,"designInfo":45,"detailedDescription":48,"studyPopulation":49,"armGroups":50,"interventions":44,"overallOfficials":44,"centralContacts":53,"locations":59,"responsibleParty":78,"collaborators":44,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":44,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":44,"studyType":94,"phases":44,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":62,"whyStopped":44,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Chinese University of Hong Kong","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":44},[9],{"measure":10,"description":11,"timeFrame":12},"The change in Framingham Risk Score between baseline and 1-year after ADT.","The Framingham Risk Score is a gender-specific algorithm based on multiple cardiovascular risk factors including age, smoking status, blood pressure level, serum total cholesterol and HDL-cholesterol level for the estimation of the 10-year risk of developing cardiovascular disease. This remain a commonly used assessment for cardiovascular risk, including PCa patients treated with ADT internationally.","From enrollment to 1-year after ADT",[14,17,20,23,26,29,32,35,38,41],{"measure":15,"description":16,"timeFrame":12},"Incidence of new-onset diabetes","Incidence of new-onset diabetes after ADT",{"measure":18,"description":19,"timeFrame":12},"Incidence of new-onset hypertension","Incidence of new-onset hypertension after ADT",{"measure":21,"description":22,"timeFrame":12},"Changes in fasting blood sugar","Changes in fasting blood sugar (serum level)",{"measure":24,"description":25,"timeFrame":12},"Changes in LDL-Cholesterol","Changes in LDL-Cholesterol (serum level)",{"measure":27,"description":28,"timeFrame":12},"Changes in HDL-cholesterol","Changes in HDL-cholesterol (serum level)",{"measure":30,"description":31,"timeFrame":12},"Changes in triglyceride","Changes in triglyceride (serum level)",{"measure":33,"description":34,"timeFrame":12},"Changes in HbA1c","Changes in HbA1c (serum level)",{"measure":36,"description":37,"timeFrame":12},"Incidence of additional medical therapies for optimization of cardiovascular risk","Number of additional cardiovascular medical therapies",{"measure":39,"description":40,"timeFrame":12},"Change in pulse wave velocity","Change in pulse wave velocity assessed by the Vascular Profiler-1000 machine (Omron, Kyoto, Japan) using the oscillometric cuff technique",{"measure":42,"description":43,"timeFrame":12},"Change in Quality of life","EQ-5D (EuroQol 5 dimensions) questionnaire Quality of life measured by ED-5Q questionnaire, with 5 components \\[Mobility, Self Care, Usual Activities, Pain\u002FDiscomfort, and Anxiety\u002FDepression)\\], and a Visual analogue scale from 0 to 100 (EQ-VAS) score, the higher the score the better in quality of life",null,{"allocation":44,"interventionModel":44,"interventionModelDescription":44,"primaryPurpose":44,"observationalModel":46,"timePerspective":47,"maskingInfo":44},"COHORT","PROSPECTIVE","Prostate Cancer (PCa) and androgen deprivation therapy (ADT) PCa is the most common cancer and the second leading cancer death in adult male globally. In Hong Kong, it is one of the most rapidly increasing cancer and is now the third most common cancer and the 4th leading cancer death in male. Despite the increased usage of serum PSA for early cancer diagnosis, more than 50% of patients were diagnosed at stage III \\& IV, with lymph node +\u002F- bone \u002F visceral metastasis. Therefore, ADT is still commonly used in PCa patients, both as neo-adjuvant\u002F adjuvant to radiotherapy,as well as backbone therapy for metastatic disease.While the overall survival of PCa patients has been prolonged by ADT, there is also increasing concern about potential long-term side effects, in particular cardiovascular effect.\n\nTherefore, there is a need for prospective studies to understand the role of close cardiovascular assessment, monitoring and treatment on the cardiovascular risk of PCa patients receiving ADT. Information on the risk factors at baseline; follow-up, and also treatment \u002F secondary prevention adopted, will help to provide evidence to fill the current knowledge gap and build practical guidelines for clinical usage. In the long run, the data will also help to estimate the medical resources required for future health care planning to cope with the medical needs of the rapidly increasing PCa population.","prostate cancer patients receiving androgen deprivation therapy",[51],{"label":52,"type":44,"description":49,"interventionNames":44},"PCa receiving ADT",[54],{"name":55,"role":56,"phone":57,"phoneExt":44,"email":58},"Chi Fai NG, Professor","CONTACT","852-3505-3933","ngcf@surgery.cuhk.edu.hk",[60],{"facility":61,"status":62,"city":63,"state":44,"zip":44,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"The Chinese University of Hong Kong","RECRUITING","Hong Kong","HK",{"type":66,"coordinates":67},"Point",[68,69],114.17469,22.27832,{"lat":69,"lon":68},[72,75],{"name":73,"role":56,"phone":57,"phoneExt":44,"email":74},"Sui Yan LAU","beckylau@surgery.cuhk.edu.hk",{"name":76,"role":77,"phone":44,"phoneExt":44,"email":44},"CHI FAI NG, Professor","PRINCIPAL_INVESTIGATOR",{"type":77,"investigatorFullName":79,"investigatorTitle":80,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"NG Chi Fai","Professor","100528680","the-effect-of-multidisciplinary-care-approach-on-cv-risk-modification-in-cap-patients-receiving-adt-100528680",false,"NCT06163924","The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT","To Investigate the Effect of Multidisciplinary Care Approach on Cardiovascular Risk Modification in Prostate Cancer Patients Receiving Androgen Deprivation Therapy","Inclusion Criteria:\n\n* Adult men 18-80 years old\n* With histological proven prostate cancer or clinically diagnosed to have prostate cancer,\n* Planned for ADT for at least 1 year\n\nExclusion Criteria:\n\n* Subjects with established major atherosclerotic cardiovascular disease (ASCVD) as defined by a recent acute coronary syndrome within the past 12 months, a history of myocardial infarction other than the recent acute coronary syndrome event, a history of ischemic stroke, and symptomatic peripheral arterial disease (defined as history of claudication with ankle-brachial index \\<0.85 or previous revascularization or amputation\n* Prior neoadjuvant or adjuvant hormone therapy within 1 year before\n* Refuse or unable to give written informed consent\n* Participation in an investigational program with interventions outside of routine clinical practice","MALE","18 Years","80 Years",{"count":92,"type":93},130,"ESTIMATED","OBSERVATIONAL","Prostate cancer is characterised by its slow progression nature, and even for metastatic disease, the 5-year survival is up to 30%. While ADT can effectively control disease, there is increasing evidence suggesting that it can also result in many adverse cardiovascular side effects on the patients, and these effects are particularly important due to the prolonged survival of these patients. There are suggestions that close cardiovascular (CV) monitoring will help to reduce cardiovascular risk and related morbidities. However, there is limited data to show the positive impact of these monitoring could reducing CV risk and morbidities. Moreover, information regarding the optimal follow-up approach and schedule is also lacking. Therefore, there is a need to have more information on the approach to monitoring the CV risk and the real-life impact of this monitoring on our patients. Patients diagnosed with prostate cancer and plan to receive ADT are invited to participate in this study to assess the potential benefit of multidisciplinary care approach to CV risk modification.",[97,98],"Cardiovascular Risk","Prostate Cancer",[98,100],"Androgen deprivation Therapy","2026-10-04",{"date":103,"type":104},"2026-10-06","ACTUAL",{"date":106,"type":104},"2023-12-10",{"date":108,"type":93},"2029-03-31",{"name":5,"class":6},1]